Título / Title

PROFILE OF PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH ANTI-ANGIOGENIC THERAPY

Introdução / Purpose

To verify the profile regarding time of diagnosis of diabetes mellitus (DM), best corrected visual acuity (BCVA) and central macular thickness (CMT) of patients with DME treated with anti-angiogenic.

Material e Método / Methods

Retrospective study using data records from Hospital de olhos de Feira de Santana-CLIHON (Feira de Santana, Ba) and iRetina Eye Institute (Salvador, Ba) diabetic patients who received intravitreal administration of anti-VEGF to treat DME between April 2012 and December 2016. Inclusion criteria: patients with DME verified by fundoscopic examination and optical coherence tomography (OCT) treated with anti- angiogenic. Exclusion criteria: any other cause of macular edema instead of DM. The analyzed variables were time of DM, BCVA and CMT measured by OCT.

Resultados / Results

A total of 40 patients were included, with a mean age of 57.3 years. The mean DM time was 14.8 years and BCVA varied between 20/20 and 20/800. Nineteen patients (49%) had BCVA between 20/50 and 20/100. The mean CMT corresponded to 388.78 μm. Among 16 patients with DM time less than or equal to 10 years, 05 had BCVA worse than 20/100 and 06 between 20/50 and 20/100. Among 13 patients with DM over 10 years and less than or equal to 20 years, 06 had BCVA worse than 20/100. Six patients had DM over 20 years and all had a CMT between 250 and 350 μm. Among 16 patients with a thickness between 250 and 350 μm, 09 had BCVA between 20/50 and 20/100. And among 16 patients with a thickness above 350 μm, 07 had AV of 20/50 to 20/100 and 06 worse than 20/100.

Discussão e Conclusões / Conclusion

This study presents the real life profile of patients treated with anti-angiogenic therapy for EMD. The patients started the treatment with worse visual acuity and greater macular thickness. The delay in treatment is possibly due to socioeconomic and cultural conditions. More study should be conducted to better characterize these facts.

Palavras Chave

diabetes, diabetic macular edema, antiangiogenic